Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Yvonne L. Greenstreet M.B.A., M.D. | CEO & Director | 4.25M | 5.73M | 1963 |
| Dr. Phillip A. Sharp Ph.D. | Co-Founder, Member of the Scientific Advisory Board & Independent Director | 105k | -- | 1945 |
| Mr. Jeffrey V. Poulton M.B.A. | CFO & Executive VP | 1.43M | -- | 1968 |
| Dr. Kevin Joseph Fitzgerald Ph.D. | Executive VP, Chief Scientific Officer and Head of Early Research & Early Development | 1.23M | 3.77M | 1969 |
| Dr. Pushkal P. Garg M.D. | Chief Medical Officer and Executive VP of Development & Medical Affairs | 1.42M | -- | 1968 |
| Mr. Tolga Tanguler M.B.A. | Executive VP & Chief Commercial Officer | 1.31M | -- | 1973 |
| Mr. Timothy J. Maines | Chief Technical Operations & Quality Officer | -- | -- | -- |
| Mr. Piyush Sharma J.D. | Chief Ethics & Compliance Officer | -- | -- | -- |
| Mr. Robert W. Hesslein Esq., J.D. | Executive VP, Chief Legal Officer & Corporate Secretary | -- | -- | 1953 |
| Ms. Christine Regan Lindenboom | Chief Corporate Communications Officer | -- | -- | 1982 |
Alnylam Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 2,230
Description
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Corporate Governance
Upcoming Events
April 30, 2025 at 12:30 PM UTC - May 5, 2025 at 12:30 PM UTC
Alnylam Pharmaceuticals, Inc. Earnings Date
Recent Events
August 22, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission